Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epidemiologic Determinants of Seroreactivity to Human Papillomavirus (HPV) Type 16 Virus-Like Particles in Cervical HPV-16 DNA—Positive and —Negative Women

Epidemiologic Determinants of Seroreactivity to Human Papillomavirus (HPV) Type 16 Virus-Like... The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA–positive and –negative women participating in a nested case-control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA–negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA–negative, seroreactivity odds ratios increased from 2.9 for 2–5 male sex partners (vs. 0 or 1) to 5.4 for 6–9 partners and 14.0 for ⩾10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA–negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA–negative subjects with use for ⩾10 years. Consequently, a possible role for virus–steroid hormone interactions in seroconversion is suggested. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Infectious Diseases Oxford University Press

Epidemiologic Determinants of Seroreactivity to Human Papillomavirus (HPV) Type 16 Virus-Like Particles in Cervical HPV-16 DNA—Positive and —Negative Women

Loading next page...
 
/lp/oxford-university-press/epidemiologic-determinants-of-seroreactivity-to-human-papillomavirus-FUSa8yBlg4

References (23)

Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
Subject
Major Articles
ISSN
0022-1899
eISSN
1537-6613
DOI
10.1093/infdis/174.5.937
Publisher site
See Article on Publisher Site

Abstract

The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA–positive and –negative women participating in a nested case-control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA–negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA–negative, seroreactivity odds ratios increased from 2.9 for 2–5 male sex partners (vs. 0 or 1) to 5.4 for 6–9 partners and 14.0 for ⩾10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA–negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA–negative subjects with use for ⩾10 years. Consequently, a possible role for virus–steroid hormone interactions in seroconversion is suggested.

Journal

Journal of Infectious DiseasesOxford University Press

Published: Nov 1, 1996

There are no references for this article.